Immunoglobulin Or Antibody Is Chimeric, Mutated, Or A Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobuin Fusion Protein, Etc.) Patents (Class 435/328)
-
Publication number: 20130129732Abstract: Method for producing microbially stabilized foods characterized in that a food containing a dialkyl dicarbonate is treated by means of electroporation.Type: ApplicationFiled: August 26, 2010Publication date: May 23, 2013Applicant: LANXESS Deutschland GmbHInventors: Rebecca Lässker, Edwin Ritzer
-
Publication number: 20130129728Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.Type: ApplicationFiled: June 22, 2011Publication date: May 23, 2013Applicant: The Regents of the University of Colorado, a Body CorporateInventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik
-
Publication number: 20130129723Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: December 29, 2010Publication date: May 23, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan
-
Publication number: 20130129729Abstract: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.Type: ApplicationFiled: August 6, 2012Publication date: May 23, 2013Inventors: Roman KISCHEL, Tobias Raum, Bernd Schlereth, Doris Rau, Ronny Cierpka, Peter Kufer
-
Publication number: 20130130372Abstract: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: ApplicationFiled: January 29, 2013Publication date: May 23, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20130130379Abstract: The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: October 12, 2012Publication date: May 23, 2013Applicant: Ablynx N.V.Inventor: Ablynx N.V.
-
Publication number: 20130129735Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: January 31, 2013Publication date: May 23, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130129721Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: ApplicationFiled: December 19, 2012Publication date: May 23, 2013Applicant: G2 INFLAMMATION PTY LTDInventor: G2 INFLAMMATION PTY LTD
-
Publication number: 20130131322Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.Type: ApplicationFiled: May 17, 2011Publication date: May 23, 2013Applicant: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
-
Publication number: 20130123471Abstract: The invention discloses a humanized chimeric monoclonal antibody against carcinoembryonic antigen (CEA), polynucleotides encoding the antibody, expression vectors comprising the polynucleotides, and host cells containing the expression vectors. The invention also discloses uses of the antibody, polynucleotides, vectors and host cells for manufacturing medicaments for diagnosis and/or treatment of tumors.Type: ApplicationFiled: March 16, 2011Publication date: May 16, 2013Applicant: Shanghai Haikang Pharmaceutical Tech. & Deve. Co., LTDInventors: Zhihua Yang, Yuliang Ran
-
Publication number: 20130115657Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.Type: ApplicationFiled: October 26, 2012Publication date: May 9, 2013Applicant: MedImmune, LLC.Inventor: MedImmune, LLC.
-
Publication number: 20130115208Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: May 13, 2011Publication date: May 9, 2013Applicant: RINAT NEUROSCIENCE CORP.Inventors: Wei-Hsien Ho, Jaume Pons, Arvind Rajpal, Pavel Strop
-
Publication number: 20130115215Abstract: Described herein is an antibody format, which is amenable to bispecific antibody creation. This format is referred to herein as “Domain Insertion Immunoglobulin G” or “(Di-IgG)”. The Di-IgG molecules are capable of specifically binding two different antigens simultaneously, show high level recombinant expression, and are sufficiently aggregation-free to be amenable to commercial production. Further described herein are, Di-IgG-encoding nucleic acids and vectors, host cells for making Di-IgGs, Di-IgG pharmaceutical compositions, and methods of treatment.Type: ApplicationFiled: July 14, 2011Publication date: May 9, 2013Inventor: Hongxing Zhou
-
Patent number: 8435513Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: July 8, 2009Date of Patent: May 7, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Publication number: 20130108638Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.Type: ApplicationFiled: December 21, 2012Publication date: May 2, 2013Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AGInventors: Novartis AG, Xoma Technology Ltd.
-
Publication number: 20130108640Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.Type: ApplicationFiled: October 22, 2012Publication date: May 2, 2013Inventors: Dan ALLISON, Carol Raport
-
Publication number: 20130110249Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating 5*. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.Type: ApplicationFiled: May 3, 2011Publication date: May 2, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Edward M. Schwarz, Mark A. Sullivan, John L. Daiss
-
Publication number: 20130108635Abstract: The present invention provides methods, compositions, and kits for the treatment of matrix mineralization disorders such as hypophosphatasia. In particular, the present invention provides polypeptides having a soluble alkaline phosphatase fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to patients, e.g., subcutaneously, to treat hypophosphatasia using enzyme replacement therapy. The invention also features nucleic acids encoding such polypeptides and the use of the nucleic acids for treating matrix mineralization disorders.Type: ApplicationFiled: April 29, 2011Publication date: May 2, 2013Inventors: Philippe Crine, Pierre Leonard
-
Publication number: 20130101549Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.Type: ApplicationFiled: October 25, 2012Publication date: April 25, 2013Applicant: BIOGEN IDEC MA INC.Inventor: BIOGEN IDEC MA INC.
-
Publication number: 20130102072Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: ApplicationFiled: December 13, 2012Publication date: April 25, 2013Applicant: THERAPEUTIC HUMAN POLYCLONALS, INC.Inventor: THERAPEUTIC HUMAN POLYCLONALS, INC.
-
Publication number: 20130095097Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.Type: ApplicationFiled: December 29, 2010Publication date: April 18, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan
-
Publication number: 20130095526Abstract: An anti-A? oligomer humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of A? amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.Type: ApplicationFiled: November 15, 2012Publication date: April 18, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventor: Kyowa Hakko Kirin Co., Ltd.
-
Publication number: 20130095098Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.Type: ApplicationFiled: March 9, 2011Publication date: April 18, 2013Applicant: UCB Pharma S.A.Inventor: Kerry Louise Tyson
-
Publication number: 20130095102Abstract: Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.Type: ApplicationFiled: June 7, 2011Publication date: April 18, 2013Applicant: ZymoGenetics, Inc.Inventors: Steven D. Levin, Margaret D. Moore, Craig D. Ostrander, Katherine E. Lewis, David W. Taft, Robert J. Rosler, Anitra Wolf, Megan M. Lantry
-
Publication number: 20130089542Abstract: An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject.Type: ApplicationFiled: October 5, 2012Publication date: April 11, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Samsung Electronics Co. Ltd.
-
Publication number: 20130089543Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: December 3, 2012Publication date: April 11, 2013Applicant: The USA, as represented by the Secretary, Dept. of Health & Human ServicesInventor: The USA, as represented by the Secretary, Dept.
-
Publication number: 20130089549Abstract: The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.Type: ApplicationFiled: May 26, 2011Publication date: April 11, 2013Applicants: SICHUAN UNIVERSITY, CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.Inventors: Li Yang, Yuquan Wei
-
Publication number: 20130089540Abstract: The present invention discloses methods of design and preparation for a new humanized anti-CD20 monoclonal antibody, related genes, protein sequence, and the use of said antibody. Comparing to murine-derived antibodies and human-mouse chimeric antibodies, said humanized anti-CD20 antibody maintains or improves high binding activity of the variable regions, meanwhile reduces the immunogenicity of chimeric antibodies, consequently achieves the effect of reducing medicine side effects and improving clinical treatment. The antibody disclosed by the present invention is efficiently expressed in animal cells, can be used for industrial production. It could be used in treating B cell lymphoma, leukaemia, or B cell-associated autoimmune disease with a wide application prospect.Type: ApplicationFiled: March 16, 2011Publication date: April 11, 2013Applicant: BIOEX THERAPEUTICS, INC.Inventors: Jie Liu, Yongke Zhang
-
Publication number: 20130089554Abstract: This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders.Type: ApplicationFiled: December 29, 2010Publication date: April 11, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan, Sateesh Kumar Natarajan, Paul A. Algate, Ruth A. Chenault
-
Publication number: 20130089550Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.Type: ApplicationFiled: December 10, 2012Publication date: April 11, 2013Inventors: Gregory A. Lazar, Matthew J. Bernett
-
Publication number: 20130089546Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.Type: ApplicationFiled: November 2, 2010Publication date: April 11, 2013Applicant: UNIVERSITY OF WASHINGTONInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
-
Publication number: 20130084284Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 17, 2012Publication date: April 4, 2013Inventors: Pablo Umaña, Ekkehard Mössner
-
Publication number: 20130084295Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: December 3, 2012Publication date: April 4, 2013Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Publication number: 20130078249Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 21, 2012Publication date: March 28, 2013Inventors: Oliver Ast, Peter Bruenker, Tanja Fauti, Anne Freimoser-Grundschober, Christiane Jaeger, Christian Klein, Ekkehard Moessner, Pablo Umana
-
Publication number: 20130078250Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 21, 2012Publication date: March 28, 2013Inventors: Oliver Ast, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo Umana
-
Publication number: 20130078248Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: ApplicationFiled: March 29, 2012Publication date: March 28, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
-
Publication number: 20130078216Abstract: The present invention relates to molecules that can be targeted to the liver. These liver targeting molecules (e.g.fusions and conjugates) comprise proteins, antibodies or antibody fragments such as immunoglobulin (antibody) single variable domains (dAbs) and also one or more additional molecules which it is desired to deliver to the liver such as interferons. The invention further relates to uses, formulations, compositions and devices comprising such liver targeting molecules. The invention also relates to immunoglobulin (antibody) single variable domains which bind to hepatocytes.Type: ApplicationFiled: January 13, 2011Publication date: March 28, 2013Inventors: Grainne Dunlevy, Steven Holmes, Zhi Hong, Armin Sepp, Adam Walker
-
Patent number: 8404233Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.Type: GrantFiled: May 15, 2008Date of Patent: March 26, 2013Assignee: Smart Targeting LimitedInventors: Makoto Sunamura, Hideo Yagita
-
Publication number: 20130071379Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: May 8, 2012Publication date: March 21, 2013Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20130071413Abstract: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.Type: ApplicationFiled: August 22, 2012Publication date: March 21, 2013Applicant: AUGMENTA BIOLOGICALS, LLCInventor: Paul M. Simon
-
Publication number: 20130071381Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: June 20, 2012Publication date: March 21, 2013Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20130071324Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: ApplicationFiled: February 9, 2011Publication date: March 21, 2013Applicants: PERSEUS PROTEOMICS INC., FUJIFILM RI PHARMA CO., LTD.Inventors: Akihiro Hino, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Publication number: 20130065299Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.Type: ApplicationFiled: August 17, 2012Publication date: March 14, 2013Applicant: Acceleron Pharma, Inc.Inventors: John Knopf, Jasbir Seehra
-
Publication number: 20130064817Abstract: Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.Type: ApplicationFiled: November 7, 2012Publication date: March 14, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Leonard G. Presta
-
Patent number: 8394928Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: August 26, 2010Date of Patent: March 12, 2013Assignee: Roche Glycart AGInventors: Johannes Auer, Birgit Bossenmaier, Guy Georges, Alexander Lifke, Ekkehard Moessner, Gerhard Niederfellner
-
Patent number: 8394926Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.Type: GrantFiled: December 21, 2006Date of Patent: March 12, 2013Assignee: Micromet AGInventors: Ralf Lutterbüse, Petra Mayer, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
-
Publication number: 20130058937Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 21, 2012Publication date: March 7, 2013Inventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
-
Publication number: 20130058927Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: ApplicationFiled: October 31, 2012Publication date: March 7, 2013Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
Publication number: 20130058936Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: August 21, 2012Publication date: March 7, 2013Inventors: Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo Umana -
Publication number: 20130060011Abstract: The present invention relates to bispecific antibodies comprising at least two fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: August 21, 2012Publication date: March 7, 2013Inventors: Peter Bruenker, Christiane Jaeger, Christian Klein, Wolfgang Schaefer, Pablo Umana